Avanos Medical (AVNS)
(Delayed Data from NYSE)
$21.18 USD
+1.79 (9.23%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $21.18 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.18 USD
+1.79 (9.23%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $21.18 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth A Momentum C VGM
Zacks News
Neogen (NEOG) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Neogen (NEOG) delivers core growth in both the Food Safety and Animal Safety segments amid macroeconomic headwinds in the third quarter.
Catalent (CTLT) New Launch to Aid TPD Programs, Clinical Trials
by Zacks Equity Research
Catalent's (CTLT) latest launch will likely aid in advancing the rational selection of orally developable TPD candidates and their progress into clinical trials.
UnitedHealth (UNH) Arm to Reduce Prior Authorization Time
by Zacks Equity Research
UnitedHealth's (UNH) UnitedHealthcare business to lower the use of prior authorization process or preauthorization by almost 20%.
Tenet Healthcare (THC) Jumps 14.9% YTD: More Growth Ahead?
by Zacks Equity Research
Tenet Healthcare's (THC) focus on boosting USPI's network is positioning the company for expedited growth.
QIAGEN (QGEN) QIAxcel Connect Gets Red Dot Design Award
by Zacks Equity Research
QIAGEN (QGEN) QIAxcel Connect automates the analysis of the size and quality of isolated DNA and RNA.
Teleflex (TFX) Urolift Market Expansion Strong, Cost Woe Stays
by Zacks Equity Research
Teleflex (TFX) plans to spend 2023 training surgeons, building its presence in key cities and continuing to engage with the Chinese Urological Society to build acceptance.
Thermo Fisher (TMO) Partners With ArsenalBio for Cancer R&D
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with ArsenalBio supports the latter's clinical manufacturing of autologous T-cell therapies for advanced cancer treatment.
Here's Why Investors Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its planned geographic expansion.
Illumina (ILMN) to Enable Tertiary Analysis With New Launch
by Zacks Equity Research
Illumina's (ILMN) Connected Software is an end-to-end software system that standardizes analysis tools and connects data across the genomics workflow.
Reasons to Add The Cooper Companies (COO) to Your Portfolio
by Zacks Equity Research
The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.
Surmodics (SRDX) Gets FDA's Formal Feedback About SurVeil DCB
by Zacks Equity Research
Surmodics' (SRDX) receipt of the FDA's positive formal feedback regarding its PMA application for the SurVeil DCB looks promising.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Here's Why You Should Retain Avantor (AVTR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Avantor's (AVTR) strong product portfolio.
Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion
by Zacks Equity Research
Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.
NextGen's (NXGN) New Cloud-Based Solution to Improve Workflow
by Zacks Equity Research
NextGen's (NXGN) latest product is expected to simplify connectivity for healthcare providers, thereby solving clinical data exchange challenges.
CVS Health (CVS) Nears Completion of $8B SGFY Acquisition
by Zacks Equity Research
According to CVS Health (CVS), Signify Health, a leading healthcare platform, is set to play a critical role in advancing its healthcare services strategy.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on solid fourth-quarter 2022 performance and its strategies to accelerate growth.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The U.S. Healthcare segment of Walgreens Boots (WBA) grows on key contract wins, continued partnership growth and a strong focus on execution during fiscal Q2.
Elevance (ELV) Arm to Bring Virtual-First Plans to Georgia
by Zacks Equity Research
The cocktail of virtual and in-person options from Elevance Health's (ELV) part of the Anthem family of brands is expected to enrich members' health experience.
Thermo Fisher (TMO) Opens New Cell Therapy Facility at UCSF
by Zacks Equity Research
Thermo Fisher's (TMO) new cell therapy facility at UCSF is likely to accelerate the development of advanced therapies.
Quest Diagnostics (DGX) Introduces New Post-COVID-19 Panels
by Zacks Equity Research
Quest Diagnostics' (DGX) latest panels provide consumers a deeper look into their health, helping to prepare them for meaningful discussions with their healthcare providers
Walgreens Boots (WBA) Benefits From Innovation Amid Margin Woe
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline reflects lower demand for COVID-19 services.
Here's Why You Should Retain Inogen (INGN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Abbott's (ABT) CardioMEMS Favors Heart Failure Management
by Zacks Equity Research
Abbott (ABT) announces key findings from meta-analysis, which shows remote pressure monitoring to be a life-extending option among heart failure patients.
Catalent (CTLT) Inks Deal for Nasal Spray for Opioid Overdoses
by Zacks Equity Research
Catalent's (CTLT) latest commercial supply agreement is expected to combat the opioid epidemic by making OTC naloxone more widely and easily accessible.